Analyst: Novo Nordisk's estimated sales growth decrease not as big as expected
A general price squeeze and lower sales in China will be evident in Novo Nordisk's sales growth next year, but the predicted impact is less significant than anticipated, says a Sydbank analyst.
by marketwire, translated by daniel pedersen
On Friday, Novo Nordisk reports that global sales growth will be negatively affected by a 3 percent sales growth decrease in 2022 because of a new Chinese insulin tender model, resulting in lower prices and volumes of insulin sold in China.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Novo Nordisk gets obesity drug approved in Canada
For subscribers
